Tauns Laboratories (TSE:197A) Debt-to-Asset : 0.33 (As of Jun. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Tauns Laboratories Debt-to-Asset?

Tauns Laboratories's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was 円5,232 Mil. Tauns Laboratories's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was 円4,307 Mil. Tauns Laboratories's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2024 was 円29,261 Mil. Tauns Laboratories's debt to asset for the quarter that ended in Jun. 2024 was 0.33.

Tauns Laboratories Debt-to-Asset Historical Data

The historical data trend for Tauns Laboratories's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tauns Laboratories Debt-to-Asset Chart

Tauns Laboratories Annual Data

Trend

Jun22

Jun23

Jun24

Debt-to-Asset

0.24

0.35

0.33

Tauns Laboratories Semi-Annual Data
	Jun22	Jun23	Jun24
Debt-to-Asset	0.24	0.35	0.33

Competitive Comparison of Tauns Laboratories's Debt-to-Asset

For the Medical Instruments & Supplies subindustry, Tauns Laboratories's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tauns Laboratories's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Tauns Laboratories's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Tauns Laboratories's Debt-to-Asset falls into.

Tauns Laboratories Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Tauns Laboratories's Debt-to-Asset for the fiscal year that ended in Jun. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(5232	+	4307)	/	29261.325
	=	0.33

Tauns Laboratories's Debt-to-Asset for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(5232	+	4307)	/	29261.325
	=	0.33

Tauns Laboratories (TSE:197A) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Tauns Laboratories Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Tauns Laboratories's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Tauns Laboratories Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Tauns Laboratories Inc (TSE:197A) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

761-1 Kamishima Izunokuni-shi, Shizuoka, JPN, 410-2325

Website

https://www.tauns.co.jp/en

Tauns Laboratories Inc is engaged in development, manufacture and sales of in vitro diagnostics and research reagents. Its product include Capilia Flu Neo, Capilia Adeno Neo, Capilia RSV Neo, Capilia hMPV, etc.

Tauns Laboratories Headlines

No Headlines